Low-Dose Yellow Fever Vaccine in Adults in Africa
Authors:
Open Access
- 20 February 2025
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (8) , 788-797
Abstract
Yellow fever vaccine is highly effective with a single dose, but vaccine supply is limited. The minimum dose requirements for seroconversion remain unknown. In this double-blind, randomized, noninferiority trial in Uganda and Kenya, we assigned adults with no history of yellow fever vaccination or infection to receive vaccination with the Institut Pasteur de Dakar 17D-204 yellow fever vaccine at a standard dose (13,803 IU) or at a fractional dose of 1000 IU, 500 IU, or 250 IU. The primary outcome was seroconversion at 28 days after vaccination with each fractional dose as compared with the standard dose, evaluated in a noninferiority analysis. Seroconversion was defined as an antibody titer at day 28 that was at least four times as high as the antibody titer before vaccination, as measured by a plaque reduction neutralization test. We conducted noninferiority analyses in the per-protocol and intention-to-treat populations. Noninferiority was shown if the lower boundary of the 95% confidence interval for the difference in the incidence of seroconversion between the fractional dose and the standard dose was higher than -10 percentage points. A total of 480 participants underwent randomization (120 participants in each group). The incidence of seroconversion was 98% (95% confidence interval [CI], 94 to 100) with the standard dose. The difference in the incidence of seroconversion between the 1000-IU dose and the standard dose was 0.01 percentage points (95% CI, -5.0 to 5.1) in the intention-to-treat population and -1.9 percentage points (95% CI, -7.0 to 3.2) in the per-protocol population; the corresponding differences between the 500-IU dose and the standard dose were 0.01 percentage points (95% CI, -5.0 to 5.1) and -1.8 percentage points (95% CI, -6.7 to 3.2), and those between the 250-IU dose and the standard dose were -4.4 percentage points (95% CI, -9.4 to 0.7) and -6.7 percentage points (95% CI, -11.7 to 1.6). A total of 111 vaccine-related adverse events were reported: 103 were mild in severity, 7 were moderate, and 1 was severe. The incidence of adverse events was similar in the four groups. A yellow fever vaccination dose as low as 500 IU was noninferior to the standard dose of 13,803 IU for producing seroconversion within 28 days. (Funded by the European and Developing Countries Clinical Trials Partnership and the Wellcome Trust; NIFTY ClinicalTrials.gov number, NCT04059471.).Keywords
Funding Information
- European and Developing Countries Clinical Trials Partnership (EDCTP- RIA2016V-1633)
- Wellcome Trust (203077_Z_16_Z)
This publication has 19 references indexed in Scilit:
- Safety of the yellow fever vaccine in people living with HIV: a longitudinal study exploring post-vaccination viremia and hematological and liver kineticsThe Brazilian Journal of Infectious Diseases, 2024
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trialThe Lancet Infectious Diseases, 2023
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trialThe Lancet Infectious Diseases, 2023
- Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trialsJournal of Medical Virology, 2023
- Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trialThe Lancet, 2021
- Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patientsAIDS, 2018
- Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern DayCurrent Infectious Disease Reports, 2017
- Fractional dosing of yellow fever vaccine to extend supply: a modelling studyThe Lancet, 2016
- Yellow Fever in Angola and Beyond — The Problem of Vaccine Supply and DemandNew England Journal of Medicine, 2016
- Yellow feverJournal of Clinical Virology, 2015